The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

The Toxicity Profile of Concurrent Nivolumab and Ipilimumab

Harriet Kluger, MD
Published Online: 8:01 PM, Fri October 3, 2014
Harriet Kluger, MD, associate professor of medicine, Yale Cancer Center, discusses the toxicity profile of concurrent nivolumab and ipilimumab as seen in a phase I trial.

Clinical Pearls

  • Additive toxicity was found between these agents.
  • The grade 3/4 adverse event rate was greater than 50%.
  • Most adverse events were reversible with immunosuppressants.

<<< View more from the 2014 ESMO Congress

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.